Related Experiment Video
Updated: Aug 6, 2026
04:36
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
miR-330-3p Inhibits the Development of Acute Myeloid Leukemia by Targeting SYTL4
Yuanyuan Zhang1, Anni Xu2, Huiling Qin3,4
1Internal Medicine Base Training, Shanghai Fengxian District Central Hospital, Shanghai, China.
Summary
MicroRNA-330-3p (miR-330-3p) is reduced in Acute Myeloid Leukemia (AML). Upregulating miR-330-3p inhibits AML progression by targeting SYTL4, suggesting its potential as a diagnostic and prognostic biomarker.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- MicroRNAs (miRNAs) are key regulators in cancer development.
- Reduced miR-330-3p levels are observed in Acute Myeloid Leukemia (AML).
Purpose of the Study:
- To investigate the regulatory role and mechanisms of miR-330-3p in AML progression.
- To evaluate miR-330-3p as a potential biomarker for AML diagnosis and prognosis.
Main Methods:
- Quantitative real-time PCR (qRT-PCR) for miR-330-3p expression analysis.
- Clinical relevance assessed using chi-square, ROC, Cox, and Kaplan-Meier survival analyses.
- Functional impact on AML cells evaluated via CCK8 and Transwell assays; target validation using luciferase assays.
Main Results:
- miR-330-3p expression was significantly decreased in AML patients.
- Low miR-330-3p levels correlated with adverse clinical features and poorer survival outcomes.
- miR-330-3p upregulation suppressed AML cell proliferation, migration, and invasion.
- SYTL4 was identified as a direct target of miR-330-3p, and both were involved in AML development.
Conclusions:
- miR-330-3p inhibits AML development by targeting SYTL4.
- miR-330-3p demonstrates potential as a valuable diagnostic and prognostic biomarker for AML.
